The competent authorities are proceeding with a preventive control of a specific batch of the anticoagulant drug Warfant 3 mg, following information that some packages may contain tablets of 1 mg instead of 3 mg.
According to an announcement by the Health Insurance Organization, the issue concerns exclusively batch 25002 of the product WARFANT TABLET 3MG.
The HIO was informed about this by the Pharmaceutical Services and sent a text message to beneficiaries who had been administered the drug after the circulation of the specific batch.
Patients are asked to examine the tablets in their packaging. The 3 mg tablets should be light blue. If they are a different colour or there is any doubt, the packaging should be taken to the nearest pharmacy for inspection.
In its urgent information, the company clarifies that after consultation with the Pharmaceutical Services and the marketing authorization holder, no recall will be carried out by pharmacies at this stage
Stocks in batch 25002 remain available provided that each package is checked before it is disposed of.
In particular, pharmacies are invited to:
Open the package in the presence of the patient before each sale or administration.
Confirm that the tablets are light blue.
Do not have the product if they find tablets of a different color and inform the company immediately.
To contact pharmacies or patients to whom they had already supplied products of the specific batch.
The company says pharmacies will be compensated for any defective packaging found during the inspection. Newer instructions are expected when a new, unaffected batch is available.
What patients should do
Warfant is an anticoagulant drug, and its dosage is determined individually, based on medical guidelines and INR tests. Taking a tablet of less than indicated could lead to insufficient anticoagulant effect.
For this reason, patients receiving Warfant 3 mg of batch 25002 should seek immediate control by a pharmacist. They should not stop treatment, change the dose or take additional tablets on their own initiative. Any change should only be made on the instructions of a doctor, pharmacist or the competent service for monitoring anticoagulant treatment.
